{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:41:23Z","timestamp":1790185283351,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10787-025-01709-x","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T12:24:11Z","timestamp":1742127851000},"page":"2179-2189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic effect of formononetin in 6-OHDA induced Parkinson disease in rats"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-0688","authenticated-orcid":false,"given":"Tanvi Dayanand","family":"Pingale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girdhari Lal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"1709_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fneur.2019.00399","volume":"10","author":"ST Auti","year":"2019","unstructured":"Auti ST, Kulkarni YA (2019) Neuroprotective effect of cardamom oil against aluminum induced neurotoxicity in rats. Front Neurol 10:399. https:\/\/doi.org\/10.3389\/fneur.2019.00399","journal-title":"Front Neurol"},{"key":"1709_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182\u2013217. https:\/\/doi.org\/10.1124\/pr.110.002642","journal-title":"Pharmacol Rev"},{"key":"1709_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3791\/59596","volume":"12","author":"HA Bounds","year":"2019","unstructured":"Bounds HA, Poeta DL, Klinge PM, Burwell RD (2019) Paw-print analysis of contrast-enhanced recordings (PrAnCER): a low-cost, open-access automated gait analysis system for assessing motor deficits. J vis Exp 12:150. https:\/\/doi.org\/10.3791\/59596","journal-title":"J vis Exp"},{"issue":"suppl 2","key":"1709_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/PL00007758","volume":"247","author":"H Braak","year":"2000","unstructured":"Braak H, Braak E (2000) Pathoanatomy of Parkinson\u2019s disease. J Neurol 247(suppl 2):3\u201310. https:\/\/doi.org\/10.1007\/PL00007758. (PMID: 10991663)","journal-title":"J Neurol"},{"key":"1709_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH (2009) Nonmotor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464\u2013474. https:\/\/doi.org\/10.1016\/S1474-4422(09)70068-7","journal-title":"Lancet Neurol"},{"issue":"15","key":"1709_CR6","doi-asserted-by":"publisher","first-page":"1368765","DOI":"10.3389\/fphar.2024.1368765","volume":"10","author":"M Ding","year":"2024","unstructured":"Ding M, Bao Y, Liang H, Zhang X, Li B, Yang R, Zeng N (2024) Potential mechanisms of formononetin against inflammation and oxidative stress: a review. Front Pharmacol 10(15):1368765. https:\/\/doi.org\/10.3389\/fphar.2024.1368765","journal-title":"Front Pharmacol"},{"key":"1709_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS (2019) Emerging therapies in Parkinson disease: repurposed drugs and new approaches. Nat Rev Neurol 15:204\u2013223. https:\/\/doi.org\/10.1038\/s41582-019-0155-7","journal-title":"Nat Rev Neurol"},{"key":"1709_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","volume":"82","author":"GL Ellman","year":"1959","unstructured":"Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70\u201377","journal-title":"Arch Biochem Biophys"},{"key":"1709_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neurobiolaging.2018.01.020","volume":"65","author":"G Giraldo","year":"2018","unstructured":"Giraldo G, Brooks M, Giasson BI, Janus C (2018) Locomotor differences in mice expressing wild-type human \u03b1-synuclein. Neurobiol Aging 65:140\u2013148. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.01.020","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1709_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bbr.2011.12.007","volume":"230","author":"KE Glajch","year":"2012","unstructured":"Glajch KE, Fleming SM, Surmeier DJ, Osten P (2012) Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson\u2019s disease. Behav Brain Res 230(2):309\u2013316. https:\/\/doi.org\/10.1016\/j.bbr.2011.12.007","journal-title":"Behav Brain Res"},{"issue":"9","key":"1709_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.900809","volume":"31","author":"C Gu","year":"2022","unstructured":"Gu C, Zhang Q, Li Y, Li R, Feng J, Chen W, Ahmed W, Soufiany I, Huang S, Long J, Chen L (2022) The PI3K\/AKT pathway-the potential key mechanisms of traditional chinese medicine for stroke. Front Med (Lausanne) 31(9):900809. https:\/\/doi.org\/10.3389\/fmed.2022.900809","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"1709_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/01616412.2017.1352185","volume":"39","author":"Z Hadadianpour","year":"2017","unstructured":"Hadadianpour Z, Fatehi F, Ayoobi F, Kaeidi A, Shamsizadeh A, Fatemi I (2017) The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson\u2019s disease. Neurol Res 39(9):845\u2013851. https:\/\/doi.org\/10.1080\/01616412.2017.1352185. (Epub 2017 Jul 12 PMID: 28701075)","journal-title":"Neurol Res"},{"key":"1709_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.pbb.2014.06.005","volume":"124","author":"P Kale","year":"2014","unstructured":"Kale P, Addepalli V (2014) Augmentation of antidepressant effects of duloxetine and bupropion by caffeine in mice. Pharmacol Biochem Behav 124:238\u2013244. https:\/\/doi.org\/10.1016\/j.pbb.2014.06.005","journal-title":"Pharmacol Biochem Behav"},{"key":"1709_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainresbull.2009.06.018","volume":"80","author":"E Kovari","year":"2009","unstructured":"Kovari E, Horvath J, Bouras C (2009) Neuropathology of Lewy body disorders. Brain Res Bull 80:203\u2013210. https:\/\/doi.org\/10.1016\/j.brainresbull.2009.06.018","journal-title":"Brain Res Bull"},{"issue":"1","key":"1709_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/ijms22010218","volume":"22","author":"A Kury\u0142owicz","year":"2020","unstructured":"Kury\u0142owicz A (2020) The role of isoflavones in type 2 diabetes prevention and treatment-a narrative review. Int J Mol Sci 22(1):218. https:\/\/doi.org\/10.3390\/ijms22010218","journal-title":"Int J Mol Sci"},{"key":"1709_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2020.100037","volume":"2","author":"A Lama","year":"2020","unstructured":"Lama A, Pirozzi C, Avagliano C (2020) Nutraceuticals: an integrative approach to starve Parkinson\u2019s disease. Brain Behav Immun Health 2:100037. https:\/\/doi.org\/10.1016\/j.bbih.2020.100037","journal-title":"Brain Behav Immun Health"},{"key":"1709_CR17","doi-asserted-by":"publisher","unstructured":"Liu, Qiyu and Yi, Xinyi and Dong, Zhentao and Xu, Lingyun and Yu, Zejun and Zhang, Hongling and Wu, Haoming and Mei, Zhinan and Li, Yang, Neuroprotective effects of formononetin on Parkinson\u2019s disease via inhibiting Jak2\/Stat3 and Bax\/Bcl-2 Pathways. 2014. Available at SSRN: https:\/\/ssrn.com\/abstract=4820651 or https:\/\/doi.org\/10.2139\/ssrn.4820651","DOI":"10.2139\/ssrn.4820651"},{"key":"1709_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265\u2013275","journal-title":"J Biol Chem"},{"key":"1709_CR19","doi-asserted-by":"publisher","unstructured":"L\u00fcck H (1965) Catalase. In: Bergmeyer H-U(ed) Methods of enzymatic analysis, New York, NY; London: Academic Press 885\u201394. doi.org\/https:\/\/doi.org\/10.1016\/B978-0-12-395630-9.50158-4","DOI":"10.1016\/B978-0-12-395630-9.50158-4"},{"issue":"5","key":"1709_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/cancers11050611","volume":"11","author":"SKL Ong","year":"2019","unstructured":"Ong SKL, Shanmugam MK, Fan L, Fraser SE, Arfuso F, Ahn KS, Sethi G, Bishayee A (2019) Focus on formononetin: anticancer potential and molecular targets. Cancers (Basel) 11(5):611. https:\/\/doi.org\/10.3390\/cancers11050611","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1709_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3389\/fphar.2018.00739","volume":"18","author":"MJ Oza","year":"2018","unstructured":"Oza MJ, Kulkarni YA (2018) Formononetin treatment in type 2 diabetic rats reduces insulin resistance and hyperglycemia. Front Pharmacol 18(9):739. https:\/\/doi.org\/10.3389\/fphar.2018.00739","journal-title":"Front Pharmacol"},{"key":"1709_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/0003-2697(86)90026-6","volume":"154","author":"F Paoletti","year":"1986","unstructured":"Paoletti F, Aldinucci D, Mocali A, Caparrini A (1986) A sensitive spectrophotometric method for the determination of superoxide dismutase activity in tissue extracts. Anal Biochem 154:536\u2013541","journal-title":"Anal Biochem"},{"key":"1709_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2020.173060","volume":"199","author":"T Pingale","year":"2020","unstructured":"Pingale T, Gupta GL (2020) Classic and evolving animal models in Parkinson\u2019s disease. Pharmacol Biochem Behav 199:173060. https:\/\/doi.org\/10.1016\/j.pbb.2020.173060. (Epub 2020 Oct 19 PMID: 33091373)","journal-title":"Pharmacol Biochem Behav"},{"key":"1709_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","volume":"10","author":"L Puspita","year":"2017","unstructured":"Puspita L, Chung SY, Shim JW (2017) Oxidative stress and cellular pathologies in Parkinson\u2019s disease. Mol Brain 10:53. https:\/\/doi.org\/10.1186\/s13041-017-0340-9","journal-title":"Mol Brain"},{"issue":"13","key":"1709_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.905898","volume":"30","author":"J Tian","year":"2022","unstructured":"Tian J, Wang XQ, Tian Z (2022) Focusing on formononetin: recent perspectives for its neuroprotective potentials. Front Pharmacol 30(13):905898. https:\/\/doi.org\/10.3389\/fphar.2022.905898","journal-title":"Front Pharmacol"},{"issue":"1","key":"1709_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mds.10305","volume":"18","author":"D Twelves","year":"2003","unstructured":"Twelves D, Perkins KS, Counsell C (2003) Systematic review of incidence studies of Parkinson\u2019s disease. Mov Disord 18(1):19\u201331. https:\/\/doi.org\/10.1002\/mds.10305. (PMID: 12518297)","journal-title":"Mov Disord"},{"issue":"9","key":"1709_CR27","doi-asserted-by":"publisher","first-page":"10052","DOI":"10.3390\/molecules170910052","volume":"17","author":"Y Wang","year":"2012","unstructured":"Wang Y, Zhu Y, Gao L, Yin H, Xie Z, Wang D, Zhu Z, Han X (2012) Formononetin attenuates IL-1\u03b2-induced apoptosis and NF-\u03baB activation in INS-1 cells. Molecules 17(9):10052\u201310064. https:\/\/doi.org\/10.3390\/molecules170910052","journal-title":"Molecules"},{"key":"1709_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2147\/JIR.S345895","volume":"15","author":"Y Zhong","year":"2022","unstructured":"Zhong Y, Cai X, Ding L, Liao J, Liu X, Huang Y, Chen X, Long L (2022) Nrf2 inhibits the progression of Parkinson\u2019s disease by upregulating AABR07032261.5 to repress pyroptosis. J Inflamm Res 15:669\u2013685. https:\/\/doi.org\/10.2147\/JIR.S345895","journal-title":"J Inflamm Res"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01709-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:01:58Z","timestamp":1744416118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01709-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01709-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Animal Ethics Committee (IAEC) (approval number: IAEC\/VIP\/2022\/Sept\/01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}